IL116122A - Intermediates for the history of 0-cyclic heterocyclic amines - Google Patents

Intermediates for the history of 0-cyclic heterocyclic amines

Info

Publication number
IL116122A
IL116122A IL11612292A IL11612292A IL116122A IL 116122 A IL116122 A IL 116122A IL 11612292 A IL11612292 A IL 11612292A IL 11612292 A IL11612292 A IL 11612292A IL 116122 A IL116122 A IL 116122A
Authority
IL
Israel
Prior art keywords
mmol
formula
phenyl
alkyl
ethyl
Prior art date
Application number
IL11612292A
Other languages
English (en)
Hebrew (he)
Original Assignee
Eisai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai Co Ltd filed Critical Eisai Co Ltd
Publication of IL116122A publication Critical patent/IL116122A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Production Of Liquid Hydrocarbon Mixture For Refining Petroleum (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
IL11612292A 1991-03-28 1992-03-22 Intermediates for the history of 0-cyclic heterocyclic amines IL116122A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67691891A 1991-03-28 1991-03-28
IL101327A IL101327A (en) 1991-03-28 1992-03-22 HISTORY OF TROCCYLIC-CYCLE AMINES AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM

Publications (1)

Publication Number Publication Date
IL116122A true IL116122A (en) 1998-10-30

Family

ID=24716559

Family Applications (3)

Application Number Title Priority Date Filing Date
IL101327A IL101327A (en) 1991-03-28 1992-03-22 HISTORY OF TROCCYLIC-CYCLE AMINES AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM
IL11612292A IL116122A (en) 1991-03-28 1992-03-22 Intermediates for the history of 0-cyclic heterocyclic amines
IL11612295A IL116122A0 (en) 1991-03-28 1992-03-22 Intermediates to heterocyclic-cyclic amine derivatives

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IL101327A IL101327A (en) 1991-03-28 1992-03-22 HISTORY OF TROCCYLIC-CYCLE AMINES AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL11612295A IL116122A0 (en) 1991-03-28 1992-03-22 Intermediates to heterocyclic-cyclic amine derivatives

Country Status (29)

Country Link
EP (1) EP0646115B1 (es)
JP (3) JP2659107B2 (es)
KR (1) KR0179054B1 (es)
CN (1) CN1044242C (es)
AT (1) ATE231505T1 (es)
AU (2) AU658194B2 (es)
BR (1) BR9205811A (es)
CA (2) CA2195129C (es)
CZ (1) CZ289756B6 (es)
DE (1) DE69232907T2 (es)
DK (1) DK0646115T3 (es)
EG (1) EG20281A (es)
ES (1) ES2188584T3 (es)
FI (1) FI934223A0 (es)
HU (1) HU225047B1 (es)
IE (1) IE920980A1 (es)
IL (3) IL101327A (es)
MX (1) MX9201419A (es)
MY (1) MY108885A (es)
NO (1) NO304071B1 (es)
NZ (3) NZ242151A (es)
PL (3) PL170567B1 (es)
PT (1) PT100300B (es)
RU (1) RU2119920C1 (es)
SG (1) SG49055A1 (es)
UA (1) UA45944C2 (es)
WO (1) WO1992017475A1 (es)
YU (1) YU31392A (es)
ZA (1) ZA922239B (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5750542A (en) 1993-09-28 1998-05-12 Pfizer Benzisoxazole and benzisothizole derivatives as cholinesterase inhibitors
EP0602242A4 (en) * 1991-08-22 1994-06-29 Yoshitomi Pharmaceutical Benzisoxazole compound and use thereof.
EP0535496A1 (en) * 1991-09-25 1993-04-07 Hoechst-Roussel Pharmaceuticals Incorporated (1-Indanon-2yl)methylpiperidines, intermediates and a process for their preparation and their use as medicaments
DE69332691T2 (de) * 1992-11-23 2003-12-18 Aventis Pharmaceuticals Inc., Cincinnati Substituierte 3-(aminoalkylamino)-1,2-benzisoxazole und verwandte verbindungen
US5494908A (en) * 1992-11-23 1996-02-27 Hoechst-Roussel Pharmaceutical Incorporated Substituted 3-(aminoalkylamino)-1,2-benzisoxazoles and related compounds
GB9305623D0 (en) * 1993-03-18 1993-05-05 Merck Sharp & Dohme Therapeutic agents
EP0788500B1 (en) * 1994-10-26 2004-03-03 Pfizer Inc. PROCESSES AND INTERMEDIATES FOR PREPARING 5,7-DIHYDRO-3- 2- 1-BENZYLPIPERIDIN-4-YL ETHYL]-6H-PYRROLO- 4,5-f]-1,2-BENZISOXAZOL-6-ONE
US5912246A (en) * 1995-02-15 1999-06-15 Pharmacia & Upjohn Company Imidazo 1,2-a!pyridines for the treatment of CNS and cardiac diseases
EP0816362A4 (en) * 1995-03-22 1998-07-08 Taisho Pharmaceutical Co Ltd THIAZOLE DERIVATIVES
ES2157442T3 (es) * 1995-06-06 2001-08-16 Aventis Pharma Inc Derivados de benzoisoxazol y de indazol, utilizados como agentes neurolepticos.
JPH09124643A (ja) * 1995-08-14 1997-05-13 Bristol Myers Squibb Co 抗うつ作用を有する１−アリールアルキル−４−（アルコキシピリジニル）−又は４−（アルコキシピリミジニル）ピペラジン誘導体
US5916902A (en) * 1995-09-13 1999-06-29 Pfizer Inc. Processes and intermediates for preparing 5, 7-dihydro-3- 2-(1-benzylpiperidin-4-yl)ethyl-!6H-pyrrolo- 4, 5-F!-1, 2-benzisoxazol-6-one
WO1997016446A1 (en) * 1995-11-02 1997-05-09 Merck Sharp & Dohme Limited Bicyclic heteroaryl-alkylene-(homo)piperazinones and thione analogues thereof, their preparation and their use as selective agonists of 5-ht1-like receptors
FR2751412B3 (fr) * 1996-07-17 1998-09-25 Valbiofrance Methodes de diagnostic in vitro de maladies neurodegeneratives et trousses pour la mise en oeuvre de ces methodes
US6013654A (en) * 1997-08-14 2000-01-11 Pharmacia & Upjohn Company Imidazo[1,2-A]pyridines for the treatment of CNS and cardiac diseases
EP0976404A3 (en) * 1998-07-30 2001-06-27 Pfizer Products Inc. A pharmaceutical composition for the prevention and treatment of diseases of cognitive dysfunction in a mammal
CN1163224C (zh) 1998-09-30 2004-08-25 武田药品工业株式会社 改善膀胱排泄能力的药物
EP1050303A3 (en) * 1999-04-27 2003-01-15 Pfizer Products Inc. Methods and compositions for treating age-related behavioral disorders in companion animals
US6951873B1 (en) 1999-04-27 2005-10-04 Pfizer Inc. Methods for treating age-related behavioral disorders in companion animals
AU767726B2 (en) * 1999-04-30 2003-11-20 Pfizer Products Inc. Radiotracers for in vivo study of acetylcholinesterase and Alzheimer's disease
GB9914486D0 (en) 1999-06-21 1999-08-18 Smithkline Beecham Plc Medicaments
GB9917406D0 (en) 1999-07-23 1999-09-22 Smithkline Beecham Plc Compounds
GB9917408D0 (en) 1999-07-23 1999-09-22 Smithkline Beecham Plc Compounds
DE60034577T2 (de) 1999-09-01 2007-12-27 Eisai R&D Management Co., Ltd. In 4-stellung substituierte piperidinderivate
US6906083B2 (en) 2000-06-21 2005-06-14 Eisai Co., Ltd. 4-substituted piperidine compound
EP1609783A1 (en) * 2004-06-17 2005-12-28 Neuropharma S.A.U. Marine compounds with calcium channel blocking properties for Alzheimer's disease treatment
DE102005038947A1 (de) * 2005-05-18 2006-11-30 Grünenthal GmbH Substituierte Benzo[d]isoxazol-3-yl-amin-Verbindungen und deren Verwendung in Arzneimitteln
EP1907384A2 (en) * 2005-06-30 2008-04-09 Prosidion Limited Gpcr agonists
GB0519879D0 (en) 2005-09-30 2005-11-09 Astrazeneca Ab Chemical process
WO2007126041A1 (ja) 2006-04-28 2007-11-08 Eisai R & D Management Co., Ltd. ベンゾイソオキサゾール化合物
PE20090319A1 (es) * 2007-06-01 2009-03-27 Schering Corp Moduladores de gamma secretasa
US8008327B2 (en) 2008-04-29 2011-08-30 Boehringer Ingelheim International Gmbh Indazole compounds as CCR1 receptor antagonists
WO2009137338A1 (en) 2008-05-06 2009-11-12 Boehringer Ingelheim International Gmbh Pyrazole compounds as ccr1 antagonists
PE20110854A1 (es) 2008-09-26 2011-12-23 Boehringer Ingelheim Int DERIVADOS DE 1-FENIL-1H-PIRAZOLO[3,4-c]PIRIDINA-4-CARBONILAMINA COMO ANTAGONISTAS DE LOS RECEPTORES CCR1
SG172088A1 (en) * 2008-12-12 2011-07-28 Actelion Pharmaceuticals Ltd 5-amino-2-(1-hydroxy-ethyl)-tetrahydropyran derivatives
KR20120087923A (ko) 2009-10-21 2012-08-07 베링거 인겔하임 인터내셔날 게엠베하 Ｃｃｒ１ 수용체 길항제로서의 인다졸 및 피라졸로피리딘 화합물
EP2493875B1 (en) 2009-10-27 2014-08-06 Boehringer Ingelheim International GmbH Heterocyclic compounds as ccr1 receptor antagonists
CN102905532A (zh) 2010-02-09 2013-01-30 约翰斯.霍普金斯大学 用于改善认知功能的方法和组合物
JP5793182B2 (ja) 2010-04-30 2015-10-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｃｒ１受容体アンタゴニストとしてのアザインダゾールアミド化合物
WO2012087782A1 (en) 2010-12-23 2012-06-28 Boehringer Ingelheim International Gmbh Pyrazolopiperidine compounds as ccr1 receptor antagonists
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
KR102191822B1 (ko) * 2012-11-21 2020-12-16 라퀄리아 파마 인코포레이티드 다형체
AU2014228512A1 (en) 2013-03-15 2015-10-01 Agenebio, Inc. Methods and compositions for improving cognitive function
EP3827820A1 (en) 2013-03-15 2021-06-02 The Johns Hopkins University Brivaracetam for improving cognitive function
CA2986598C (en) 2015-05-22 2023-09-26 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam
RU2638155C1 (ru) * 2016-02-29 2017-12-12 Общество С Ограниченной Ответственностью "Сай Фарма" Производные бензо[d]изоксазола и их применение
WO2023016484A1 (zh) * 2021-08-10 2023-02-16 江苏恒瑞医药股份有限公司 磺酰胺衍生物、其制备方法及其在医药上的应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3488353A (en) 1967-05-29 1970-01-06 Sterling Drug Inc New 1-((2-azaindolyl)-lower-alkyl) 4-substituted-piperazines
JPS51136666A (en) * 1975-05-19 1976-11-26 Dainippon Pharmaceut Co Ltd Process for preparing 3-aminoalkyl-1,2-benzisoxazole derivatives.
US4396770A (en) * 1982-04-09 1983-08-02 Hoechst-Roussel Pharmaceuticals Inc. 1-[3-(6-Fluoro-1,2-benzisoxazol-3-yl)propyl]-4-hydroxy-4-phenylpiperidines
IL66866A (en) * 1982-04-09 1987-08-31 Hoechst Roussel Pharma 1-(3-(6-fluoro-1,2-benzisoxazol-3-yl)propyl)-4-(substituted)-piperazines and-piperidines,a process for the preparation thereof,and pharmaceutical compositions containing them
US4489075A (en) * 1982-05-15 1984-12-18 Pfizer Inc. Cyclic sulfonamidoalkyl substituted 4-piperidinoquinazoline cardiac stimulants
PH22302A (en) * 1985-02-11 1988-07-22 Fujisawa Pharmaceutical Co Piperidine compounds
DK623586A (da) * 1985-12-27 1987-06-28 Eisai Co Ltd Piperidinderivater eller salte deraf og farmaceutiske kompositioner indeholdende forbindelserne
JPS63234065A (ja) * 1987-03-23 1988-09-29 Mitsubishi Rayon Co Ltd 包接能を有する高分子組成物
JPH0657707B2 (ja) * 1987-05-25 1994-08-03 吉富製薬株式会社 ピペリジン化合物
FI95572C (fi) * 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
US4980365A (en) * 1987-07-13 1990-12-25 Hoechst-Roussel Pharmaceuticals Inc. N-substituted-5,6-dimethoxy-1,2-benzisoxazole-3-propanamine and related compounds as analgesic and hypotensive agents
DE68905845T2 (de) * 1988-02-19 1993-08-05 Lilly Co Eli Tetrazolverbindungen als antagonisten der excitatorischen aminosaeurerezeptoren.
JPH0283375A (ja) * 1988-09-21 1990-03-23 Dainippon Pharmaceut Co Ltd ２−置換ピペラジニル−２−（１，２−ベンズイソキサゾール−３−イル）酢酸誘導体
FR2654104B1 (fr) * 1989-11-07 1992-01-03 Adir Nouveaux derives du 1,2-benzisoxazole, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
EP0641320B1 (en) * 1991-04-17 2001-05-30 PHARMACIA & UPJOHN COMPANY Substituted (s)-3-phenylpiperidine derivatives, their preparation and their use as dopamine autoreceptor antagonists

Also Published As

Publication number Publication date
NZ248946A (en) 1995-04-27
YU31392A (sh) 1994-12-28
NO304071B1 (no) 1998-10-19
PT100300B (pt) 1999-09-30
NZ250987A (en) 1997-06-24
AU2178895A (en) 1995-09-07
SG49055A1 (en) 1998-05-18
CA2107105A1 (en) 1992-09-29
RU2119920C1 (ru) 1998-10-10
CA2195129A1 (en) 1992-09-29
CZ289756B6 (cs) 2002-04-17
DE69232907D1 (de) 2003-02-27
FI934223A (fi) 1993-09-27
NO933445D0 (no) 1993-09-27
ZA922239B (en) 1993-09-27
DK0646115T3 (da) 2003-04-22
IE920980A1 (en) 1992-10-07
JPH06500794A (ja) 1994-01-27
PT100300A (pt) 1993-08-31
NO933445L (no) 1993-09-27
NZ242151A (en) 1994-10-26
IL101327A (en) 1998-06-15
AU1878292A (en) 1992-11-02
PL170567B1 (pl) 1997-01-31
JP2000154185A (ja) 2000-06-06
CZ395892A3 (en) 1994-04-13
CA2107105C (en) 2003-10-07
JPH10158264A (ja) 1998-06-16
WO1992017475A1 (en) 1992-10-15
MX9201419A (es) 1992-10-01
PL171915B1 (pl) 1997-06-30
BR9205811A (pt) 1994-06-28
ATE231505T1 (de) 2003-02-15
CN1044242C (zh) 1999-07-21
IL116122A0 (en) 1996-01-31
CA2195129C (en) 2002-09-10
FI934223A0 (fi) 1993-09-27
PL171914B1 (pl) 1997-06-30
HU225047B1 (en) 2006-05-29
JP2659107B2 (ja) 1997-09-30
EG20281A (en) 1998-07-30
MY108885A (en) 1996-11-30
CN1065267A (zh) 1992-10-14
AU658194B2 (en) 1995-04-06
HU9302733D0 (en) 1993-12-28
EP0646115A1 (en) 1995-04-05
HUT68357A (en) 1995-06-28
IL101327A0 (en) 1992-11-15
EP0646115B1 (en) 2003-01-22
JP3051076B2 (ja) 2000-06-12
ES2188584T3 (es) 2003-07-01
DE69232907T2 (de) 2003-05-15
KR0179054B1 (en) 1999-03-20
UA45944C2 (uk) 2002-05-15
AU674477B2 (en) 1996-12-19

Similar Documents

Publication Publication Date Title
IL116122A (en) Intermediates for the history of 0-cyclic heterocyclic amines
US6498255B2 (en) Heterocyclic-cyclic amine derivatives as cholinesterase inhibitors
Villalobos et al. Novel benzisoxazole derivatives as potent and selective inhibitors of acetylcholinesterase
US5716967A (en) Isoxazoline compounds as antiinflammatory agents
RU2062776C1 (ru) Способ получения замещенных n-(арилоксиалкил)-гетероарилпиперидина или гетероарилпиперазина
US20060084690A1 (en) Isoxazole derivatives
US20040082607A1 (en) Fused heterocyclic compounds
EP0915847A1 (en) Substituted sulfonamides as selective beta3 agonists for the treatment of diabetes and obesity
TW201208679A (en) Sigma receptor inhibitors
TW201309670A (zh) 吲哚衍生物或其藥理學上容許之鹽
WO2008026704A1 (fr) Dérivé d'isoquinoline
KR100673341B1 (ko) 나프티리딘 유도체
EP2303871B1 (en) Pyrrolidin-3-ylmethyl-amine as orexin antagonists
HUT70051A (en) Novel tricyclic-cyclic amines as cholinesterase inhibitors, pharmaceutical compositions containing them and process for preparing them

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed